Dendreon's drug may have lost the battle for Europe before it even began.
On Monday, Johnson & Johnson (NYSE: JNJ) received approval in Europe for Zytiga as a pre-chemo treatment for prostate cancer. With Dendreon's (NASDAQ: DNDN) drug Provenge not approved in Europe yet, should investors be concerned about its ability to gain traction on the continent? Watch the following video and find out.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
